Genmab — November 2025
-
More wants more
-
Thank you
-
Er det bare mig eller bliver real world data på Epco og Glofi udlagt negativt. Man kan jo ikke sammenligne trials hvor pts skal være CD20 +ve med real world data i 3L hvor 80% af pts har tabt CD20 expression. Nogen som har et bud på om dette vil ændre peak sales på Epco ? Søg på Epcoritamab på X og jeg syntes budskabet er epco/Glofi præsterer dårligere i real life end i trials.
-
My two cents : Whereas writer – and I trust other investors - appreciate in-put with a technical background from professionals in this forum. Regrettably, however, due to use of acronyms and abbreviations in-put often becomes so technical it often comes across gobbledygook – incomprehensible to ordinary mortals (investors). Use of “simpler” terms and less acronyms etc. could enable/attract more investors to read and follow progress and in the process be attracted to support Genmab.
-
Det koster blod, sved og tåre at være investeret i biotech. Jeg har sprugt meget i flere år
Skriv en liste på alle de forkortelser og akronymer du har mødt, så er jeg sikker på de profesionelle her på PI er villige til at forklare. Det er min erfaring. -
-
Knock-Your-Socks-Off-News – November 2025 https://www.linkedin.com/pulse/knock-your-socks-off-news-november-2025-genmab-vy0ze/
-
TEPEZZA
(teprotumumab-trbw) sales increased 15% year-over-year to $560 million in the third quarter, driven by higher inventory levels and higher net selling price https://investors.amgen.com/news-releases/news-release-details/amgen-reports-third-quarter-2025-financial-results -
Genmab A/S is set to announce its Q3 2025 earnings on November 6, 2025, with analysts expecting earnings of $0.47 per share and revenue of $975.4 million https://www.marketbeat.com/instant-alerts/genmab-as-gmab-expected-to-announce-quarterly-earnings-on-thursday-2025-10-30/
-
Genmab AS (GMAB, Financial) is set to release its Q3 2025 earnings on Nov 6, 2025. The consensus estimate for Q3 2025 revenue is $986.99 million, and the earnings are expected to come in at $0.46 per share. https://www.gurufocus.com/news/3185679/genmab-as-gmab-q3-2025-earnings-report-preview-what-to-look-for
-
Regnskab vel først efter markedet i DK er lukket - oplyst efter kl. 17.00 - som sædvanligt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind